AxoSim is a life science company working to create a world where no one surrenders their identity, independence, and quality of life to neurological disease. In partnership with pharmaceutical companies, AxoSim builds human brains and peripheral nerves in the lab to heal memory, movement, and pain disorders. The proprietary brain-on-a-chip platform leverages tissue engineering, neural interfacing, and AI to test groundbreaking interventions at scale, generating human-relevant data early in the drug development process to increase the probability of success.

CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of tomorrow's medicines.

Our mission is to create a healthier society by enabling life science companies to invent novel compounds in a safer, more efficient, faster, and animal-free way. As the pioneer in engineering and industry-scale production of assay-ready 3D microtissues, InSphero provides solutions that help pharmaceutical, cosmetics, and chemical companies accelerate safety and efficacy testing, and bring better drugs to market.

InSphero provides superior biological relevance to in vitro testing with easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. Our patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain, and skin. These models help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. Microtissues are available directly or through a menu of 3D InSight™ Standard Services, supported by a comprehensive panel of 3D-optimized culture media, assay protocols, and imaging solutions. InSphero’s technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HTS-DILI, and validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer. Founded in 2009 and privately held, InSphero is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Cyclofluidic is an emerging disruptive technology platform for true Closed loop Drug Discovery that uses an unique microfluidic integrated synthesis and screening platform to dramatically reduce the design-synthesis-screen cycle time for small molecule compounds by orders of magnitude to 90 minutes allowing rapid and efficient profiling of the chemical space around your hits and leads. Cyclofluidic is based in the UK (north of London in the Cambridge Biotech corridor) and has a global business development team ready to discuss your drug discovery projects. Cyclofluidic has a vision of revolutionizing discovery, solving medicinal chemistry problems at speed, through integration of flow chemistry, purification, screening and design in a true closed loop. • Become the partner of choice with the pharmaceutical, biotech and not-for-profit drug discovery.• Translate our passion for drug discovery into pre-clinical molecules with the highest chance of becoming innovative medicines.• Impact on drug discovery through our innovation in science and business• Develop partnerships with our collaborators, leveraging the CylOps™ platform to solve medicinal chemistry problems at speed.

Simple Solutions for Complex Biology

As one of the top contract research organizations in the field of life science services, GenScript has created a one-stop, customizable service package that incorporates custom gene synthesis & cloning, peptide synthesis, protein production & purification, monoclonal & polyclonal antibody production, and siRNA & miRNA services. Our unified model and dedication to excellence makes us the ideal partner for any early-stage drug discovery project. GenScript provides direct support by acting as the client’s R&D bio-reagent center and bio-assay center. Through its customer-oriented philosophy and one-stop service model, GenScript has established fruitful goal-alignment partnerships with clients in academia, government programs, and all levels of the pharmaceutical and biotechnology industries on all five inhabited continents. GenScript continues pursuing better ways of meeting customers' challenging needs for quality services and technological innovation.

Additional responsibilities of my position include the evaluation and implementation of novel advances in assay development, screening technology, instrumentation, robotics and liquid handling. For the past two years I have chaired a multidisciplinary site-wide committee that aims to improve all aspects of the drug discovery process using informatics, automation and miniaturization.During my Pfizer career, I've received my MBA degree and have been engaged with the business side of the operation in addition to my R&D role. I'm particularly interested in Outsourcing and for the past 12 months have coordinated activities in my zone related to offshore partnerships with a number of Asian-based CROs. This included project management of ongoing programs in Asia and tactical and transactional reagent sourcing to support internal and external programs. It is in the area of business development with outsourcing and building CRO alliances that I would like to direct my future career.

Candidate gene research for Obesity and Diabetes.

Cardiovascular and Metabolic Disease research.